Non-Melanoma Skin Cancer

SITC Cancer Immunotherapy Guidelines are a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced and will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

The Non-Melanoma Skin Cancer Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with non-melanoma skin cancer (NMSC). As of January 2020, immunotherapies currently approved by the U.S. FDA for the treatment of NMSC include avelumab and pembrolizumab for patients with metastatic Merkel cell carcinoma and cemiplimab for patients with metastatic or locally advanced cutaneous squamous cell carcinoma and additional trials are ongoing. Reflecting the evolving therapeutic landscape, SITC will develop an NMSC CPG with topics including selection of appropriate immunotherapeutic regimens, recognition and management of adverse events, and patient quality of life considerations.

SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel

Christopher A. Barker, MD – Memorial Sloan Kettering Cancer Center

Carrie Best – Patient Advocate

Shailender Bhatia, MD – Fred Hutchinson Cancer Research Center, University of Washington

Kathyrn B. Bollin, MD – Scripps Health

Sunandana Chandra, MD, MS – Northwestern Medicine Feinberg School of Medicine

Zeynep Eroglu, MD – H. Lee Moffitt Cancer Center & Research Institute

Brian R. Gastman, MD – Cleveland Clinic Cancer Center

Kari L. Kendra, MD, PhD – The Ohio State University Comprehensive Cancer Center

Harriet Kluger, MD – Yale University

Evan J. Lipson, MD – Johns Hopkins University

Kathleen Madden, FNP, MSN, AOCNP, APHN – NYU Langone Perlmutter Cancer Center

David M. Miller, MD, PhD, FAAD – Massachusetts General Hospital

Paul Nghiem, MD, PhD – University of Washington

Anna C. Pavlick, DO, MBA – Weill Cornell Medicine

Igor Puzanov, MD, MSci, FACP – Roswell Park Comprehensive Cancer Center

Guilherme Rabinowits, MD – Miami Cancer Institute

Emily S. Ruiz, MD, MPH – Brigham and Women's Hospital

Vernon K. Sondak, MD – Moffitt Cancer Center & Research Institute

Michael T. Tetzlaff, MD, PhD – University of California San Francisco